Literature DB >> 14708856

Malaria status in Al-Hodeidah Governorate, Republic of Yemen. Part II: Human factors causing the persistence of chloroquine resistant P. falciparum local strain.

Mohamed T Al-Maktari1, Hassan K Bassiouny.   

Abstract

Two hundred and nine Yemeni with P. falciparum local strain satisfing all criteria of WHO for monitoring chloroquine sensitivity by in vivo and in vitro tests in urban and rural population of Al-Hodiedah G. were interviewed to study the human factors causing the persistence of chloroquine resistant. A pre-designed questionnaire sheet was used for every case, which included data concerning assessment of chloroquine resistant problem. The results revealed that, 54.7% of the studied group had used chloroquine for malaria treatment. About 75.0% were used antimalarial drugs by over the counter (OTC) i.e. self medication which was more common in rural (76.9%) than urban areas (63.6%). Chloroquine resistant was increased with the decrease of education level; decrease income/capita/month; among younger age-group (<15 years); and sleeping in open air in courts (56.3%, 57.8%, 56.6% and 66.7% respectively). The highest percentage of chloroquine resistant (71.0%) was recorded among cases with high parasite density (>1000 asexual parasite/microL); in presence of gametocytes (82.6%); among cases who did not complete antimalarial course (89.7%); those who gave a history of receiving antimalarial drugs without laboratory diagnosis (75.0%); those keeping leftover drugs after usage (63.8%) and reading expiry date and pamphlet of malaria drugs (26.9%). The results suggested the need for increasing of public awareness on emergence and spread of chloroquine-resistant and to outline potential risk factors useful for health workers in Yemen, especially in remote areas to identify high risk P. falciparum patients for chloroquine resistance before treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14708856

Source DB:  PubMed          Journal:  J Egypt Soc Parasitol        ISSN: 1110-0583


  6 in total

1.  Molecular epidemiology of Plasmodium species prevalent in Yemen based on 18 s rRNA.

Authors:  Abdulsalam Mq Al-Mekhlafi; Mohammed Ak Mahdy; Ahmed A Azazy; Mun Yik Fong
Journal:  Parasit Vectors       Date:  2010-11-19       Impact factor: 3.876

2.  High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy.

Authors:  Abdulsalam M Al-Mekhlafi; Mohammed A K Mahdy; Hesham M Al-Mekhlafi; Ahmed A Azazy; Mun Yik Fong
Journal:  Parasit Vectors       Date:  2011-05-27       Impact factor: 3.876

3.  Seroepidemiology of Plasmodium species infections in Zimbabwean population.

Authors:  Seth A Amanfo; Takafira Mduluza; Nicholas Midzi; David R Cavanagh; Francisca Mutapi
Journal:  Malar J       Date:  2016-05-10       Impact factor: 2.979

4.  Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.

Authors:  Wahib M Atroosh; Hesham M Al-Mekhlafi; Georges Snounou; Adel Al-Jasari; Hany Sady; Nabil A Nasr; Yee-Ling Lau; Johari Surin
Journal:  Malar J       Date:  2016-05-27       Impact factor: 2.979

5.  High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen.

Authors:  Ahmed A Adeel; Niaz Abdo Saeed; Adel Aljasari; Amar M Almohager; Mohamed H Galab; Amar AlMahdi; Mansor H Mahammed; Mohammed AlDarsi; Yahiya A Salaeah; Hoda Atta; Ghasem Zamani; Marian Warsame; Amy Barrette; Hanan El Mohammady; Rania A Nada
Journal:  Malar J       Date:  2015-11-14       Impact factor: 2.979

6.  Malaria in Hadhramout, a southeast province of Yemen: prevalence, risk factors, knowledge, attitude and practices (KAPs).

Authors:  Omar A A Bamaga; Mohammed A K Mahdy; Rohela Mahmud; Yvonne A L Lim
Journal:  Parasit Vectors       Date:  2014-07-29       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.